Study of Pharmacodynamic Effects of VAY736 in Patients With Primary Sjögren's Syndrome
Primary Purpose
Primary Sjögren's Syndrome
Status
Withdrawn
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
VAY736 lower dose
VAY736 higher dose
Sponsored by

About this trial
This is an interventional treatment trial for Primary Sjögren's Syndrome focused on measuring Primary Sjögren's syndrome, Sicca syndrome, Salivary glands, Positron Emission Tomography, B cell depletion
Eligibility Criteria
Part 1 and 3:
Inclusion Criteria:
- Fullfilled consensus criteria for primary Sjögren's syndrome
- Patients must have elevated serum levels for some Sögren Syndorme specific parameters such as antinuclear antibodies (ANA), rheumatoid factor (RF) etc.
Exclusion Criteria:
- Patients that are suffering from Secondary Sjögren's syndrome.
- Patients previously treated with monoclonal antibody treatments such as rituximab, infliximab, adalimumab, etc.
Part 2
Inclusion criteria:
- healthy male and female people 18-75 years of age
Exclusion criteria:
- Use of other investigational drugs at the time of enrollment
- Exposure to a sizeable degree of radiation (≥ 5 mSv) in an investigational research study in the past year prior to this study
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
VAY736 lower dose
VA736 higher dose
Arm Description
12 evaluable patients will be enrolled and randomized (at a ratio of 1:1) to receive either a lower dose or a higher dose of the study drug (VAY736)
12 evaluable patients will be enrolled and randomized (at a ratio of 1:1) to receive either a lower dose or a higher dose of the study drug (VAY736)
Outcomes
Primary Outcome Measures
Part 1: To determine the feasibility of measuring major salivary gland infiltrating B cells in pSS patients using [Zr- 89]rituximab PET/CT imaging
Part 1: PET/CT imaging of pSS major salivary gland 3, 6 and 9 days after i.v. injection with [Zr- 89]rituximab
Part 2: To define the normal range of PET/CT imaging values for major salivary gland tissue, cervical lymph nodes and spleen in healthy volunteers with [Zr-89]-rituximab
Part 2: PET/CT imaging of healthy volunteers' major salivary gland, cervical lymph nodes and spleen on optimal time point after i.v. injection with [Zr-89]-rituximab (e.g. 3 days after injection)
Part 3: To compare the effect of two different VAY736 s.c. dose regimes on salivary gland-infiltrating B cells in pSS patients, using [Zr-89]-rituximab PET/CT imaging
Part 3: PET/CT imaging of pSS tissues on optimal time point after i.v. injection with [Zr-89]-rituximab, at baseline and 12 weeks after the start of VAY736 treatment
Secondary Outcome Measures
Safety of multiple s.c. dosing of VAY736 in pSS patients as measured by safety assessments
AEs, vital signs, ECGs, safety laboratory parameters (Hematology, Biochmistry, Urinalysis)
To asses the pharmacokinetiks of VAY736 in pSS patients
Multiple s.c. dose VAY736 PK parameter - Area under the curve (AUC)
To assess the pharmacokinetiks of VAY736 in pSS patients
Multiple s.c. dose VAY736 PK parameter - Trough concentrations after multiple dose
Assess the pharmacodynamic effect of VAY736 on circulating CD19+ B-cells in pSS
Multiple s.c. dose VAY736 PD parameter - depletion of B cells
Asses effect of two different VAY736 dose levels on target tissue structure and function in pSS
Assess size of spleen and cervical lyph nodes by PET/CT imaging and ultrasound-aided size measurements
Asses effect of two different VAY736 dose levels on target tissue structure and function in pSS
Assess salivary glands size and echostructure by ultrasound
Asses effect of two different VAY736 dose levels on target tissue structure and function in pSS
Assess salivary gland function (quantitative) by salivary flow (stimulated and unstimulated)
Asses effect of two different VAY736 dose levels on target tissue structure and function in pSS
Assess lacrimal gland function by Schirmer's test
To evaluate the effect of two different VAY736 dose levels (s.c. q4w) on pSS disease activity
Assess the change in the EULAR Sjögren'sSyndrome Disease Activity Index (ESSDAI).
To evaluate the effect of on self-reported outcomes in pSS patients
Multidimensional Fatigue Inventory (MFI-20); the short form 36 health Survey (SF-36); EULAR Sjögren's Syndorm Patient Reported Intensity (ESSPRI)
To evaluate the change in the physician global assessment of patients's overall disease activity
Physician's visual anaglog scale (VAS)
To evaluate the change in the patients global assessment of their disease activity
Patient's visual analogue scale (VAS)
To assess the immunogenicity of VAY736
Anti-VAY736 antibodies
To assess the immunogenicity of a micodose of rituximab
Anti-rituximab antibodies
To asses the pharmacokinetiks of VAY736 in pSS patients
Multiple s.c. dose VAY736 PK parameter - Cmax
To asses the pharmacokinetiks of VAY736 in pSS patients
Multiple s.c. dose VAY736 PK parameter - tmax
To asses the pharmacokinetiks of VAY736 in pSS patients
Multiple s.c. dose VAY736 PK parameter - half live (t1/2)
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02495129
Brief Title
Study of Pharmacodynamic Effects of VAY736 in Patients With Primary Sjögren's Syndrome
Official Title
A Three-part, Partially Open Label and Double-blind, Randomized Study to Assess the Pharmacodynamic Effects, Safety, Tolerability and Preliminary Efficacy of VAY736 in Patients With Primary Sjögren's Syndrome Using [Zr-89]-Rituximab PET/CT
Study Type
Interventional
2. Study Status
Record Verification Date
February 2016
Overall Recruitment Status
Withdrawn
Study Start Date
December 2015 (undefined)
Primary Completion Date
September 2017 (Anticipated)
Study Completion Date
September 2017 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novartis Pharmaceuticals
4. Oversight
5. Study Description
Brief Summary
This study consists of three consecutive parts. Part 1 in primary Sjögren's syndrome (pSS) patients (n=2-6) and Part 2 in healthy voluteers (n=3) are feasibility studies to assess if the selected [Zr-89]-rituximab PET/CT method is a valid method to assess B cells in salivary glands of pSS patients. In Part 1 and Part 2 no IMP will be applied to the subjects. In Part 3, pSS patients (n=12) will receive the IMP, VAY736. Posted information will be focused on Part 3.
The overarching purpose of this study is to test a new drug (VAY736) for the treatment of pSS. In pSS, the salivary glands (the glands that produce saliva) and other organs are affected by inflammation. A certain type of white blood cells called B cells prominently infiltrate the salivary glands in pSS, whereas they are not present in healthy salivary glands. Scientific evidence suggests that B cells may be involved in the disease process in pSS and that eliminating B cells may benefit patients with pSS. This study will test a new imaging method and a new treatment for pSS. Both the imaging method and the treatment are specific for B cells.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Primary Sjögren's Syndrome
Keywords
Primary Sjögren's syndrome, Sicca syndrome, Salivary glands, Positron Emission Tomography, B cell depletion
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
VAY736 lower dose
Arm Type
Experimental
Arm Description
12 evaluable patients will be enrolled and randomized (at a ratio of 1:1) to receive either a lower dose or a higher dose of the study drug (VAY736)
Arm Title
VA736 higher dose
Arm Type
Experimental
Arm Description
12 evaluable patients will be enrolled and randomized (at a ratio of 1:1) to receive either a lower dose or a higher dose of the study drug (VAY736)
Intervention Type
Drug
Intervention Name(s)
VAY736 lower dose
Intervention Description
Patients will receive a total number of 3 monthly subcutaneous injections with the lower dose of VAY736
Intervention Type
Drug
Intervention Name(s)
VAY736 higher dose
Intervention Description
Patients will receive a total number of 3 monthly subcutaneous injections with the higher dose of VAY736
Primary Outcome Measure Information:
Title
Part 1: To determine the feasibility of measuring major salivary gland infiltrating B cells in pSS patients using [Zr- 89]rituximab PET/CT imaging
Description
Part 1: PET/CT imaging of pSS major salivary gland 3, 6 and 9 days after i.v. injection with [Zr- 89]rituximab
Time Frame
Part 1: 4 weeks
Title
Part 2: To define the normal range of PET/CT imaging values for major salivary gland tissue, cervical lymph nodes and spleen in healthy volunteers with [Zr-89]-rituximab
Description
Part 2: PET/CT imaging of healthy volunteers' major salivary gland, cervical lymph nodes and spleen on optimal time point after i.v. injection with [Zr-89]-rituximab (e.g. 3 days after injection)
Time Frame
Part 2: 4 weeks
Title
Part 3: To compare the effect of two different VAY736 s.c. dose regimes on salivary gland-infiltrating B cells in pSS patients, using [Zr-89]-rituximab PET/CT imaging
Description
Part 3: PET/CT imaging of pSS tissues on optimal time point after i.v. injection with [Zr-89]-rituximab, at baseline and 12 weeks after the start of VAY736 treatment
Time Frame
Part 3: 12 weeks
Secondary Outcome Measure Information:
Title
Safety of multiple s.c. dosing of VAY736 in pSS patients as measured by safety assessments
Description
AEs, vital signs, ECGs, safety laboratory parameters (Hematology, Biochmistry, Urinalysis)
Time Frame
12 weeks
Title
To asses the pharmacokinetiks of VAY736 in pSS patients
Description
Multiple s.c. dose VAY736 PK parameter - Area under the curve (AUC)
Time Frame
12 weeks
Title
To assess the pharmacokinetiks of VAY736 in pSS patients
Description
Multiple s.c. dose VAY736 PK parameter - Trough concentrations after multiple dose
Time Frame
12 weeks
Title
Assess the pharmacodynamic effect of VAY736 on circulating CD19+ B-cells in pSS
Description
Multiple s.c. dose VAY736 PD parameter - depletion of B cells
Time Frame
12 weeks
Title
Asses effect of two different VAY736 dose levels on target tissue structure and function in pSS
Description
Assess size of spleen and cervical lyph nodes by PET/CT imaging and ultrasound-aided size measurements
Time Frame
12 weeks
Title
Asses effect of two different VAY736 dose levels on target tissue structure and function in pSS
Description
Assess salivary glands size and echostructure by ultrasound
Time Frame
12 weeks
Title
Asses effect of two different VAY736 dose levels on target tissue structure and function in pSS
Description
Assess salivary gland function (quantitative) by salivary flow (stimulated and unstimulated)
Time Frame
12 weeks
Title
Asses effect of two different VAY736 dose levels on target tissue structure and function in pSS
Description
Assess lacrimal gland function by Schirmer's test
Time Frame
12 weeks
Title
To evaluate the effect of two different VAY736 dose levels (s.c. q4w) on pSS disease activity
Description
Assess the change in the EULAR Sjögren'sSyndrome Disease Activity Index (ESSDAI).
Time Frame
12 weeks
Title
To evaluate the effect of on self-reported outcomes in pSS patients
Description
Multidimensional Fatigue Inventory (MFI-20); the short form 36 health Survey (SF-36); EULAR Sjögren's Syndorm Patient Reported Intensity (ESSPRI)
Time Frame
12 weeks
Title
To evaluate the change in the physician global assessment of patients's overall disease activity
Description
Physician's visual anaglog scale (VAS)
Time Frame
12 weeks
Title
To evaluate the change in the patients global assessment of their disease activity
Description
Patient's visual analogue scale (VAS)
Time Frame
12 weeks
Title
To assess the immunogenicity of VAY736
Description
Anti-VAY736 antibodies
Time Frame
12 weeks
Title
To assess the immunogenicity of a micodose of rituximab
Description
Anti-rituximab antibodies
Time Frame
25 weeks
Title
To asses the pharmacokinetiks of VAY736 in pSS patients
Description
Multiple s.c. dose VAY736 PK parameter - Cmax
Time Frame
12 weeks
Title
To asses the pharmacokinetiks of VAY736 in pSS patients
Description
Multiple s.c. dose VAY736 PK parameter - tmax
Time Frame
12 weeks
Title
To asses the pharmacokinetiks of VAY736 in pSS patients
Description
Multiple s.c. dose VAY736 PK parameter - half live (t1/2)
Time Frame
12 weeks
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Part 1 and 3:
Inclusion Criteria:
Fullfilled consensus criteria for primary Sjögren's syndrome
Patients must have elevated serum levels for some Sögren Syndorme specific parameters such as antinuclear antibodies (ANA), rheumatoid factor (RF) etc.
Exclusion Criteria:
Patients that are suffering from Secondary Sjögren's syndrome.
Patients previously treated with monoclonal antibody treatments such as rituximab, infliximab, adalimumab, etc.
Part 2
Inclusion criteria:
- healthy male and female people 18-75 years of age
Exclusion criteria:
Use of other investigational drugs at the time of enrollment
Exposure to a sizeable degree of radiation (≥ 5 mSv) in an investigational research study in the past year prior to this study
12. IPD Sharing Statement
Learn more about this trial
Study of Pharmacodynamic Effects of VAY736 in Patients With Primary Sjögren's Syndrome
We'll reach out to this number within 24 hrs